fda glp-1 warning letters news Issues 30 to Telehealth Firms Over Misleading Compounded Marketing Drug ad enforcement ramps up–again

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

has released a white paper, Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes, providing insight into the success of compounded medication users within the Hims & Hers weight loss program

Just remembermedication works best alongside healthy habits and guidance from your care team.

Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use

On average, studies show most people living with obesity lose between 15% and 25% of their body weight after just one year on a GLP-1

Building on the foundation of HITI, we have developed derivative methods such as SATI, HITI-TE, and Gene-DUET, which show promise for use in inherited disease models, including Hutchinson-Gilford Progeria Syndrome, Inherited GPI Deficiency, and Spinal Muscular Atrophy 7,10,11